Biomedical Advanced Research and Development Authority (BARDA)
330 C Street, SW
Room G640
Washington
D.C.
20201
United States
Tel: 202-260-1200
Fax: 202-205-4520
212 articles with Biomedical Advanced Research and Development Authority (BARDA)
-
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
3/9/2023
MediciNova, Inc. announced a modification to its contract with the BARDA, a part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services, to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury.
-
Immunyx Pharma Selected to Join BLUE KNIGHT™
1/23/2023
Immunyx Pharma announced it has been selected to join Blue Knight , a collaboration between Johnson & Johnson Innovation LLC and the Biomedical Advanced Research and Development Authority ('BARDA') within the Administration for Strategic Preparedness and Response (ASPR), a part of the U.S. Department of Health and Human Services, (HHS).
-
HDT Bio Selected to Join BLUE KNIGHT™
11/7/2022
HDT Bio Corp. announced it has been selected to join Blue Knight, a collaboration between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority within the Administration for Strategic Preparedness and Response, a part of the U.S. Department of Health and Human Services.
-
Hologic Announces Contract with BARDA to Support IVD Approval of COVID Assays
11/2/2022
Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $19 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to support research and development efforts.
-
Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
10/27/2022
Soligenix, Inc. announced today that the Company has been invited by the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures to submit a full contract proposal for the development of single-vial, adjuvanted, heat stable subunit vaccines to prevent filovirus infection.
-
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
10/4/2022
Vir Biotechnology, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, has awarded Vir a multi-year contract with the potential for up to $1 billion to advance the development of a full portfolio of innovative solutions to address influenza and potentially other infectious disease threats.
-
Venatorx Pharmaceuticals Awarded BARDA Project BioShield Contract
10/3/2022
Venatorx Pharmaceuticals today announced the Biomedical Advanced Research and Development Authority has awarded the company a contract to support the development of cefepime-taniborbactam for the treatment of melioidosis.
-
T2 Biosystems Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million
9/29/2022
T2 Biosystems, Inc. announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, is providing an additional $3.7 million in funding for the multiple-year cost-share contract.
-
Funding initiatives this week saw money flow into cancer, rare liver diseases, respiratory depression, chemotherapy-related toxicities and a cutting-edge machine learning platform.
-
Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular (“IM”) Formulation of ENA-001
9/27/2022
Eagle Pharmaceuticals, Inc. and Enalare Therapeutics Inc. announced that Enalare has secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services.
-
Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)
9/22/2022
Marinus Pharmaceuticals, Inc. today announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, exercised its first contract option, valued at approximately $12.3 million.
-
Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine
9/14/2022
The Sabin Vaccine Institute announced it is receiving an additional $21.8 million under an existing contract with the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services.
-
Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox
8/29/2022
Chimerix today announced that is has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), for the delivery of up to 1.7 million treatment courses of tablet and suspension formulations of TEMBEXA® to the U.S. government.
-
Selux Diagnostics Receives $8.0 Million in Additional Funding to Redefine Speed in Microbiology Laboratory Testing
7/12/2022
Selux Diagnostics, Inc. announced that it has been awarded an additional $8.0 million from the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response.
-
Bavarian Nordic announced the U.S. Biomedical Advanced Research and Development Authority has ordered an additional 500,000 doses of its monkeypox vaccine, Jynneos.
-
In partnership with the U.S. government, Evonik Industries is investing more than $200 million to build a lipid manufacturing facility in the United States.
-
Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.
-
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
4/6/2022
Vir Biotechnology, Inc. announced that a team of three company scientists were named one of the winners of the Pediatric COVID-19 Data Challenge, sponsored by the Biomedical Advanced Research and Development Authority and the U.S. Department of Health and Human Services.
-
T2 Biosystems Announces BARDA Exercise of Contract Option 2B Valued at $4.4 Million
3/31/2022
T2 Biosystems, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, is providing an additional $4.4 million in funding for the multiple-year cost-share contract between BARDA and T2 Biosystems.
-
Visby Medical Executes Contract Option with BARDA for $25.5M to Develop Rapid Flu-COVID PCR Test Designed for At-Home Use
3/25/2022
Visby Medical™, a leading medical diagnostic company, announced that it has received an additional $25.5M in federal funding to develop and validate an at-home combination Flu-Covid test from the Biomedical Advanced Research and Development Authority.